false
00000
0001941029
TW
0001941029
2025-07-18
2025-07-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
July 18, 2025
Date of Report (Date of earliest event reported)
Advanced Biomed Inc.
(Exact name of Company as specified in its charter)
| Nevada |
|
001-42548 |
|
87-2177170 |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of Incorporation) |
|
|
|
Identification Number) |
No. 689-85 Xiaodong Road, Yongkang District
Tainan City, Taiwan
(Address of principal executive offices)
886-6-3121716
(Registrant’s telephone number including area
code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
| |
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section 12(b) of
the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock |
|
ADVB |
|
The Nasdaq Stock Market LLC |
Item 3.01 Notice of Delisting or Failure to Satisfy
a Continued Listing Rule or Standard; Transfer of Listing.
On July 18, 2025, Advanced Biomed Inc. (the “Company”)
received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”)
notifying the Company that, for the last 32 consecutive business days, the bid price for the Company’s common stock had closed below
the minimum $1.00 per share requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Minimum
Bid Price Requirement”).
The Notice has no immediate effect on the listing
or trading of the Company’s common stock, which will continue to trade on the Nasdaq Capital Market under the symbol “ADVB.”
In accordance with Nasdaq Listing Rule 5810(c)(3)(A),
the Company has been provided a compliance period of 180 calendar days, or until January 14, 2026 (the “Compliance Period”),
to regain compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company’s common
stock must be at least $1.00 per share for a minimum of ten consecutive business days during the Compliance Period.
If the Company does not regain compliance by the end
of the Compliance Period, the Company may be eligible for an additional 180 calendar day compliance period, provided that the Company
meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq
Capital Market (except for the bid price requirement), and provides written notice to Nasdaq of its intent to cure the deficiency during
the second compliance period, including, if necessary, by effecting a reverse stock split.
The Company intends to monitor the closing bid price
of its common stock and will consider all available options to regain compliance with the Minimum Bid Price Requirement within the compliance
period.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking
statements, including those related to the Company’s intent to regain compliance with Nasdaq’s continued listing requirements.
Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those stated
or implied. These risks are detailed from time to time in the Company’s filings with the U.S. Securities and Exchange Commission.
The Company disclaims any obligation to update these forward-looking statements, except as required by law.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
Advanced Biomed Inc. |
| |
|
|
| Date: July 24, 2025 |
By: |
/s/ Yi Lu |
| |
|
Yi Lu |
| |
|
Chief Executive Officer |
